| Primary |
| Product Used For Unknown Indication |
21.6% |
| Lung Infection |
18.9% |
| Endocarditis |
7.2% |
| Sepsis |
7.2% |
| Pneumonia |
5.4% |
| Status Epilepticus |
4.5% |
| Brain Abscess |
3.6% |
| Cholecystitis Acute |
3.6% |
| Pneumonia Mycoplasmal |
3.6% |
| Sinusitis |
3.6% |
| Endometritis |
2.7% |
| Epilepsy |
2.7% |
| Pain |
2.7% |
| Acute Cholecystitis |
1.8% |
| Cardiac Disorder |
1.8% |
| Gaucher's Disease |
1.8% |
| Lower Respiratory Tract Infection |
1.8% |
| Meningococcal Sepsis |
1.8% |
| Urinary Tract Infection |
1.8% |
| Vomiting |
1.8% |
|
| Drug Rash With Eosinophilia And Systemic Symptoms |
17.5% |
| Convulsion |
7.5% |
| Pyrexia |
7.5% |
| Vomiting |
7.5% |
| Acute Generalised Exanthematous Pustulosis |
5.0% |
| Aspartate Aminotransferase Increased |
5.0% |
| Paraesthesia |
5.0% |
| Rash Erythematous |
5.0% |
| Restlessness |
5.0% |
| Tachycardia |
5.0% |
| Tremor |
5.0% |
| Von Willebrand's Disease |
5.0% |
| Alanine Aminotransferase Increased |
2.5% |
| Anaphylactic Shock |
2.5% |
| Aspergillosis |
2.5% |
| Bone Marrow Failure |
2.5% |
| Bradycardia |
2.5% |
| Brain Oedema |
2.5% |
| C-reactive Protein Increased |
2.5% |
| Deafness |
2.5% |
|
| Secondary |
| Product Used For Unknown Indication |
30.4% |
| Drug Use For Unknown Indication |
10.7% |
| Pneumonia |
10.1% |
| Pneumonia Mycoplasmal |
5.9% |
| Hypertension |
5.2% |
| Hiv Infection |
4.6% |
| Infection |
3.9% |
| Arthritis Bacterial |
2.6% |
| Mycobacterium Avium Complex Infection |
2.6% |
| Pneumonia Aspiration |
2.6% |
| Prophylaxis |
2.6% |
| Sedation |
2.6% |
| Sepsis |
2.6% |
| Bacterial Infection |
2.2% |
| Type 2 Diabetes Mellitus |
2.2% |
| Endometritis |
2.0% |
| Meningitis |
2.0% |
| Staphylococcal Infection |
2.0% |
| Brain Abscess |
1.7% |
| Mycobacterium Abscessus Infection |
1.7% |
|
| Stevens-johnson Syndrome |
11.5% |
| Toxic Epidermal Necrolysis |
11.5% |
| Nosocomial Infection |
9.0% |
| Septic Shock |
7.7% |
| Pulmonary Fibrosis |
6.4% |
| Prothrombin Time Prolonged |
5.1% |
| Vasculitis |
5.1% |
| Coagulation Factor V Level Decreased |
3.8% |
| Disseminated Intravascular Coagulation |
3.8% |
| Rash |
3.8% |
| Toxic Skin Eruption |
3.8% |
| Tubulointerstitial Nephritis |
3.8% |
| Urinary Tract Infection Enterococcal |
3.8% |
| Vestibular Disorder |
3.8% |
| Vomiting |
3.8% |
| Aphasia |
2.6% |
| Cardio-respiratory Arrest |
2.6% |
| Cholelithiasis |
2.6% |
| Cholestasis |
2.6% |
| Dermatitis Exfoliative |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
18.7% |
| Surgery |
16.6% |
| Product Used For Unknown Indication |
13.7% |
| Prophylaxis |
9.4% |
| Abdominal Pain |
6.5% |
| Medical Diet |
5.4% |
| Oesophagitis |
4.3% |
| Hypertension |
3.5% |
| Hiv Infection |
3.1% |
| Hepatic Neoplasm Malignant |
2.1% |
| Foetal Exposure During Pregnancy |
2.0% |
| Gastritis |
2.0% |
| Liver Carcinoma Ruptured |
1.9% |
| Hypoalbuminaemia |
1.7% |
| Nuclear Magnetic Resonance Imaging |
1.7% |
| Pneumonia |
1.7% |
| Pyrexia |
1.5% |
| Grand Mal Convulsion |
1.4% |
| Hepatitis B |
1.4% |
| Nausea |
1.4% |
|
| Abdominal Pain |
8.4% |
| Pulmonary Embolism |
8.4% |
| Respiratory Failure |
7.8% |
| Pyrexia |
6.5% |
| Amnesia |
5.8% |
| Toxic Epidermal Necrolysis |
5.8% |
| Vomiting |
5.8% |
| Renal Failure |
4.5% |
| Sepsis |
4.5% |
| Shock |
4.5% |
| Transaminases Increased |
4.5% |
| Aspartate Aminotransferase Increased |
3.9% |
| Diarrhoea |
3.9% |
| Hepatitis |
3.9% |
| Pulmonary Haemorrhage |
3.9% |
| Renal Failure Acute |
3.9% |
| Retinopathy Of Prematurity |
3.9% |
| Hypotension |
3.2% |
| Sepsis Neonatal |
3.2% |
| Staphylococcal Sepsis |
3.2% |
|
| Interacting |
| Endocarditis |
33.3% |
| Postoperative Care |
16.7% |
| Antiplatelet Therapy |
9.3% |
| Diabetes Mellitus |
9.3% |
| Candidiasis |
7.4% |
| Pain |
7.4% |
| Cardiac Disorder |
5.6% |
| Constipation |
5.6% |
| Pyrexia |
5.6% |
|
| Drug Interaction |
40.0% |
| Rash Erythematous |
40.0% |
| Papule |
20.0% |
|
